

Aminah Jatoi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2912763/publications.pdf>

Version: 2024-02-01

300
papers

13,403
citations

66234

42
h-index

24915

109
g-index

304
all docs

304
docs citations

304
times ranked

15052
citing authors

#	ARTICLE	IF	CITATIONS
1	Dexamethasone and hiccups: a 2000-patient, telephone-based study. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e790-e793.	0.8	3
2	In Their Own Words, "Waiting Sucks": A Qualitative Study of Medical Testing-Related Anxiety in Patients with Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2023, 40, 468-474.	0.8	2
3	Frequency and Symptomatology of Hiccups in Patients With Cancer: Using an On-Line Medical Community to Better Understand the Patient Experience. <i>American Journal of Hospice and Palliative Medicine</i> , 2022, 39, 147-151.	0.8	8
4	Disparities in older adult accrual to cancer trials: Analysis from the alliance for clinical trials in oncology (A151736). <i>Journal of Geriatric Oncology</i> , 2022, 13, 20-26.	0.5	4
5	Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series. <i>Blood Cancer Journal</i> , 2022, 12, 11.	2.8	9
6	Colorectal Cancer, Crohn-Like Lymphoid Reactions, Survival " And the Power of a Good Cup of Coffee!. <i>Mayo Clinic Proceedings</i> , 2022, 97, 15-17.	1.4	1
7	Establishing the Groundwork for Clinical Trials With Hiccups [®] for Hiccup Palliation. <i>American Journal of Hospice and Palliative Medicine</i> , 2022, 39, 1210-1214.	0.8	2
8	Skeletal muscle mitochondrial dysfunction and muscle and whole body functional deficits in cancer patients with weight loss. <i>Journal of Applied Physiology</i> , 2022, 132, 388-401.	1.2	13
9	A Cautionary Tale: Grouping Patients on Late Events. <i>Mayo Clinic Proceedings</i> , 2022, 97, 449-453.	1.4	0
10	Olaparib for ovarian cancer: a single-institution, multi-site qualitative study. <i>Supportive Care in Cancer</i> , 2022, , 1.	1.0	1
11	Understanding "Patient refuses" among 90+ year old patients with cancer or presumed cancer. <i>Journal of Geriatric Oncology</i> , 2022, , .	0.5	1
12	Reply to A. Rizzo et al. <i>JCO Precision Oncology</i> , 2022, 6, e2200061.	1.5	0
13	"It's Like You Stuck a Pin in It": African American/Black Patients Describe Cutaneous Toxicity From Epidermal Growth Factor Receptor Inhibitors. <i>American Journal of Hospice and Palliative Medicine</i> , 2022, , 104990912210926.	0.8	0
14	Evaluating and palliating hiccups. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, 475-478.	0.8	3
15	Equity. <i>Cancer</i> , 2022, , .	2.0	0
16	Succinct Cancer Clinical Trial Consent Forms in Rural Patients With Cancer: A Secondary Analysis of a Randomized, Double-Blinded study. <i>Journal of Patient Experience</i> , 2022, 9, 237437352211072.	0.4	0
17	Hiccups in patients with cancer: a multi-site, single-institution study of etiology, severity, complications, interventions, and outcomes. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
18	Analysis of patient (pt) withdrawal of consent using 11,993 pts from 58 alliance for clinical trials in oncology trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6513-6513.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Understanding Verbosity: Funding Source and the Length of Consent Forms for Cancer Clinical Trials. <i>Journal of Cancer Education</i> , 2021, 36, 1248-1252.	0.6	8
20	Conversations on Cancer Chemotherapy Cessation in Patients With Advanced Cancer: Qualitative Findings From a Multi-Institutional Study. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 175-179.	0.8	0
21	Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer. <i>Pancreatology</i> , 2021, 21, 379-383.	0.5	5
22	Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729). <i>Oncologist</i> , 2021, 26, e435-e444.	1.9	5
23	HER2-overexpression/amplification and survival in patients with resectable esophageal/gastroesophageal junction adenocarcinoma (E/GJ-AC) treated with neoadjuvant carboplatin/paclitaxel-based chemoradiation.. <i>Journal of Clinical Oncology</i> , 2021, 39, 239-239.	0.8	0
24	The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids. <i>Journal of the National Cancer Institute Monographs</i> , 2021, 2021, 86-98.	0.9	17
25	Nanoliposomal irinotecan-based chemotherapy after regular irinotecan-based chemotherapy in patients with pancreas cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 402-402.	0.8	1
26	Should Loss of Appetite Be Palliated in Patients with Advanced Cancer?. Current Treatment Options in Oncology, 2021, 22, 31.	1.3	5
27	Image-guided tumor ablation in gynecologic oncology: Review of interventional oncology techniques and case examples highlighting a collaborative, multidisciplinary program. <i>Gynecologic Oncology</i> , 2021, 160, 835-843.	0.6	5
28	Metastatic or suspected metastatic cancer in patients 90 years of age or older: A single-institution, multi-site study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1220-1224.	0.5	3
29	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. <i>Oncologist</i> , 2021, 26, 610-618.	1.9	5
30	Electronic Geriatric Assessment: Is It Feasible in a Multi-Institutional Study That Included a Notable Proportion of Older African American Patients? (Alliance A171603). <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 435-441.	1.0	14
31	How Did a Multi-Institutional Trial Show Feasibility of Electronic Data Capture in Older Patients With Cancer? Results From a Multi-Institutional Qualitative Study (Alliance A171902). <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 442-449.	1.0	3
32	Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812). <i>Journal of Geriatric Oncology</i> , 2021, 12, 563-571.	0.5	5
33	Advanced ovarian cancer patients identify opportunities for prehabilitation: A qualitative study. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100731.	0.3	9
34	Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review. <i>Current Oncology Reports</i> , 2021, 23, 86.	1.8	7
35	Role of dietary carbohydrates on risk of lung cancer. <i>Lung Cancer</i> , 2021, 155, 87-93.	0.9	16
36	Observations with apelisib in older patients (≥65 year of age) with breast cancer in a non-clinical trial setting. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 15-20.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms. <i>JCO Oncology Practice</i> , 2021, 17, e1460-e1472.	1.4	3
38	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1228-1240.	1.5	2
39	Alpelisib-induced hyperglycemia in older patients with breast Cancer: Qualitative findings. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1114-1117.	0.5	4
40	Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 78-92.	157.7	230
41	Falls: descriptive rates and circumstances in age-unspecified patients with locally advanced esophageal cancer. <i>Supportive Care in Cancer</i> , 2021, 29, 733-739.	1.0	2
42	Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 210-216.	1.1	2
43	Can older patients adopt and maintain a ketogenic diet? An observational study in support of clinical trials in older patients. <i>Medicine (United States)</i> , 2021, 100, e28033.	0.4	3
44	Does the cancer geriatric assessment (GA) introduce bias into clinical trials? Observations from 988 prospectively recruited patients. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	1
45	Olanzapine for cisplatin-induced hiccups: observations from a 338-patient study. <i>Annals of Palliative Medicine</i> , 2021, .	0.5	0
46	A qualitative study of healthcare-related experiences of non-smoking women with lung cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 123-130.	1.0	4
47	How (and why) to ask the older cancer patient about sexual health and sexual minority status. <i>Journal of Geriatric Oncology</i> , 2020, 11, 576-578.	0.5	2
48	Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology. <i>Journal of Geriatric Oncology</i> , 2020, 11, 179-183.	0.5	5
49	Querying Patients With Cancer About Sexual Health and Sexual and Gender Minority Status: A Qualitative Study of Health-Care Providers. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 418-423.	0.8	6
50	Behavioral, psychological, and supportive care interventions in geriatric oncology: The Cancer and Aging Research Group infrastructure core. <i>Journal of Geriatric Oncology</i> , 2020, 11, 347-349.	0.5	4
51	Loratadine for Paclitaxel-Induced Myalgias and Arthralgias. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 235-238.	0.8	1
52	Cancer Cachexia. , 2020, , 593-597.e1.		0
53	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	0.5	17
54	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. <i>Nature Communications</i> , 2020, 11, 5173.	5.8	46

#	ARTICLE	IF	CITATIONS
55	Developing an Educational Intervention to Address Financial Hardship in Cancer Patients. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 424-433.	1.2	15
56	Methylarginine metabolites are associated with attenuated muscle protein synthesis in cancer-associated muscle wasting. <i>Journal of Biological Chemistry</i> , 2020, 295, 17441-17459.	1.6	14
57	Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. <i>Oncologist</i> , 2020, 25, e1681-e1690.	1.9	5
58	The wasting-associated metabolite succinate disrupts myogenesis and impairs skeletal muscle regeneration. <i>JCSM Rapid Communications</i> , 2020, 3, 56-69.	0.6	12
59	Adverse Event Burden Score—A Versatile Summary Measure for Cancer Clinical Trials. <i>Cancers</i> , 2020, 12, 3251.	1.7	19
60	Oral cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy. <i>Medical Hypotheses</i> , 2020, 143, 110149.	0.8	10
61	Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. <i>ESMO Open</i> , 2020, 5, e000926.	2.0	35
62	Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1501-1508.	2.9	17
63	Non-Squamous, Non-Basal Cell Cancers of the Skin: Exploring Associations Between Site of Disease and Depression. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 38, 104990912096960.	0.8	0
64	Patients' Perspectives and Advice on How to Discuss Sexual Orientation, Gender Identity, and Sexual Health in Oncology Clinics. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 1053-1061.	0.8	8
65	Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 646-652.	0.6	16
66	What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study. <i>Supportive Care in Cancer</i> , 2019, 27, 249-255.	1.0	11
67	Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 920-927.	1.3	67
68	Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?. <i>American Journal of Hospice and Palliative Medicine</i> , 2019, 36, 72-75.	0.8	3
69	Remarks on the design and analyses of longitudinal studies for cancer patients with anorexia and weight loss. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1175-1182.	2.9	6
70	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2338-2348.	0.8	56
71	Comparative Age-Based Prospective Multi-Institutional Observations of 12,367 Patients Enrolled to the American College of Surgeons Oncology Group (ACOSOG) Z901101 Trials (Alliance). <i>Annals of Surgical Oncology</i> , 2019, 26, 4213-4221.	0.7	3
72	Sarcopenia: A Time for Action. An SCWD Position Paper. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 956-961.	2.9	410

#	ARTICLE	IF	CITATIONS
73	Conversations About Financial Issues in Routine Oncology Practices: A Multicenter Study. <i>Journal of Oncology Practice</i> , 2019, 15, e690-e703.	2.5	42
74	Numbers Have Life: A Commentary on “Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit”. <i>Oncologist</i> , 2019, 24, 433-434.	1.9	0
75	Physician-Reported Experience and Understanding of Adverse Event Attribution in Cancer Clinical Trials. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 176-182.	1.2	5
76	The Need to Prioritize and Re-prioritize Palliative Care Options: Smoking Cessation as a Case-in-Point. <i>Current Treatment Options in Oncology</i> , 2019, 20, 33.	1.3	0
77	Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715). <i>Oncologist</i> , 2019, 24, e284-e291.	1.9	4
78	Poly (ADP-Ribose) Polymerase Inhibition for Chemotherapy-Induced Peripheral Neuropathy: A Meta-Analysis of Placebo-Controlled Trials. <i>Journal of Palliative Medicine</i> , 2019, 22, 977-980.	0.6	7
79	A hunger for hunger: a review of palliative therapies for cancer-associated anorexia. <i>Annals of Palliative Medicine</i> , 2019, 8, 50-58.	0.5	29
80	A Multicenter Comparison of Complementary and Alternative Medicine (CAM) Discussions in Oncology Care: The Role of Time, Patient-Centeredness, and Practice Context. <i>Oncologist</i> , 2019, 24, e1180-e1189.	1.9	17
81	Perspectives on the Medical, Quality of Life, and Economic Consequences of Hiccups. <i>Current Oncology Reports</i> , 2019, 21, 113.	1.8	16
82	Cachexia and Sarcopenia in Older Adults with Cancer: A Comprehensive Review. <i>Cancers</i> , 2019, 11, 1861.	1.7	132
83	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. <i>PLoS ONE</i> , 2019, 14, e0226440.	1.1	7
84	Characterizing cancer cachexia in the geriatric oncology population. <i>Journal of Geriatric Oncology</i> , 2019, 10, 415-419.	0.5	33
85	Acquisition of sexual orientation and gender identity data among NCI Community Oncology Research Program practice groups. <i>Cancer</i> , 2019, 125, 1313-1318.	2.0	30
86	ZIP4 Promotes Muscle Wasting and Cachexia in Mice With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells. <i>Gastroenterology</i> , 2019, 156, 722-734.e6.	0.6	82
87	Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance) Tj ETQq1 1 0.784314 rgBT /Over 24, 617-623.	1.9	22
88	Androgen Mediation” and Antiandrogens Mitigation” of the Epidermal Growth Factor Receptor (EGFR) Inhibitor”-Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series. <i>American Journal of Hospice and Palliative Medicine</i> , 2019, 36, 519-525.	0.8	4
89	Teaching Health-Care Providers to Query Patients With Cancer About Sexual and Gender Minority (SGM) Status and Sexual Health. <i>American Journal of Hospice and Palliative Medicine</i> , 2019, 36, 533-537.	0.8	8
90	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. , 2019, 14, e0226440.		0

#	ARTICLE	IF	CITATIONS
91	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. , 2019, 14, e0226440.		0
92	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. , 2019, 14, e0226440.		0
93	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. , 2019, 14, e0226440.		0
94	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. , 2019, 14, e0226440.		0
95	Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice. , 2019, 14, e0226440.		0
96	Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). Journal of Geriatric Oncology, 2018, 9, 321-328.	0.5	5
97	“Ultimately, mom has the call” Viewing clinical trial decision making among patients with ovarian cancer through the lens of relational autonomy. Health Expectations, 2018, 21, 981-989.	1.1	14
98	Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-“Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711). Journal of Thoracic Oncology, 2018, 13, 996-1003.	0.5	20
99	Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clinical Colorectal Cancer, 2018, 17, 85-96.	1.0	60
100	The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). Journal of Geriatric Oncology, 2018, 9, 228-234.	0.5	17
101	Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers. European Journal of Cardio-thoracic Surgery, 2018, 53, 1214-1222.	0.6	23
102	The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). Journal of Geriatric Oncology, 2018, 9, 221-227.	0.5	14
103	Looking Back, Looking Forward: The Ethical Framing of Complementary and Alternative Medicine in Oncology Over the Last 20 Years. Oncologist, 2018, 23, 639-641.	1.9	1
104	Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non-“Small-Cell Lung Cancer. Journal of Oncology Practice, 2018, 14, e211-e220.	2.5	19
105	Cancer in Transgender Patients: One Case in 385,820 Is Indicative of a Paucity of Data. Journal of Oncology Practice, 2018, 14, 270-272.	2.5	11
106	Prevalence and Survival Impact of Pretreatment Cancer-Associated Weight Loss: A Tool for Guiding Early Palliative Care. Journal of Oncology Practice, 2018, 14, e238-e250.	2.5	53
107	Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Research and Treatment, 2018, 171, 325-334.	1.1	3
108	Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients. Journal of Palliative Medicine, 2018, 21, 1334-1338.	0.6	8

#	ARTICLE	IF	CITATIONS
109	Nasal vestibulitis: an under-recognized and under-treated side effect of cancer treatment?. Supportive Care in Cancer, 2018, 26, 3909-3914.	1.0	2
110	Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With Cancer. American Journal of Hospice and Palliative Medicine, 2018, 35, 1384-1389.	0.8	0
111	Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance) Tj ETQq1 1 0.7+14 rgWT /Over	0.7	14
112	The Role of Systemic Inflammation in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention. JCSM Clinical Reports, 2018, 3, .	0.5	23
113	Incidence, Characteristics, and Implications of Seizures in Patients With Glioblastoma. American Journal of Hospice and Palliative Medicine, 2017, 34, 650-653.	0.8	10
114	â€™m Still Me: Inspiration and Instruction from Individuals with Brain Cancer. Journal of Health Care Chaplaincy, 2017, 23, 15-33.	0.7	9
115	The impact of a spiritual legacy intervention in patients with brain cancers and other neurologic illnesses and their support persons. Psycho-Oncology, 2017, 26, 346-353.	1.0	21
116	Genetically Predicted Telomere Length is not Associated with Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 971-974.	1.1	11
117	Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Research and Treatment, 2017, 163, 391-398.	1.1	16
118	North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogeneticâ€based dosing of irinotecan, oxaliplatin, and capecitabine as firstâ€line therapy for patients with advanced small bowel adenocarcinoma. Cancer, 2017, 123, 3494-3501.	2.0	32
119	Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecologic Oncology, 2017, 146, 64-68.	0.6	35
120	A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome. Supportive Care in Cancer, 2017, 25, 833-838.	1.0	7
121	Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. Journal of Clinical Oncology, 2017, 35, 421-431.	0.8	65
122	Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). Breast Cancer Research and Treatment, 2017, 166, 793-808.	1.1	11
123	Comparative â€œnocebo effectsâ€ in older patients enrolled in cancer therapeutic trials: Observations from a 446â€patient cohort. Cancer, 2017, 123, 4193-4198.	2.0	6
124	Overcoming obstacles in the design of cancer anorexia/weight loss trials. Critical Reviews in Oncology/Hematology, 2017, 117, 30-37.	2.0	20
125	Cancer-associated weight loss: releasing its firm grip on negative clinical outcomes. Current Opinion in Supportive and Palliative Care, 2017, 11, 259-260.	0.5	1
126	Patient and family member perspectives on searching for cancer clinical trials: A qualitative interview study. Patient Education and Counseling, 2017, 100, 349-354.	1.0	11

#	ARTICLE	IF	CITATIONS
127	EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. <i>Genes and Cancer</i> , 2017, 8, 589-599.	0.6	45
128	A Single-Institution Study of Demographics and Outcomes of Adult Patients with Multiple Cancers. <i>Cancer Control</i> , 2016, 23, 455-460.	0.7	1
129	Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance) Tj ETQq1 1 0.784314 rgBT 18	1.0	18
130	Ureteral obstruction in cancer patients: a qualitative study. <i>Psycho-Oncology</i> , 2016, 25, 605-609.	1.0	3
131	Gaps in nutritional research among older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2016, 7, 281-292.	0.5	47
132	Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. <i>Oncologist</i> , 2016, 21, 1483-1491.	1.9	64
133	Seizures in patients with primary brain tumors: what is their psychosocial impact?. <i>Journal of Neuro-Oncology</i> , 2016, 128, 285-291.	1.4	22
134	Self-reported verbal abuse in 1300+ older women within a private, tertiary women's health clinic. <i>Archives of Gerontology and Geriatrics</i> , 2016, 66, 62-65.	1.4	3
135	Menopausal hormone therapy in cancer survivors: A narrative review of the literature. <i>Maturitas</i> , 2016, 92, 86-96.	1.0	30
136	Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?. <i>Cancer Investigation</i> , 2016, 34, 531-535.	0.6	5
137	Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers. <i>Scientific Reports</i> , 2016, 6, 29831.	1.6	53
138	Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss. <i>Oncology Letters</i> , 2016, 12, 4219-4223.	0.8	41
139	“Enjoy glass of wine before eating:” a randomized trial to test the orexigenic effects of this advice in advanced cancer patients. <i>Supportive Care in Cancer</i> , 2016, 24, 3739-3746.	1.0	7
140	Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 311-316.	0.6	103
141	Ovarian cancer patients and their family members perspectives on novel vaccine and virotherapy trials. <i>Clinical Trials</i> , 2016, 13, 660-664.	0.7	1
142	Malignant Bowel Obstruction in Patients With Recurrent Ovarian Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2016, 33, 272-275.	0.8	20
143	Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of Ovarian Cancer. <i>Oncology</i> , 2016, 90, 59-68.	0.9	9
144	Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. <i>Journal of Clinical Oncology</i> , 2016, 34, 699-705.	0.8	42

#	ARTICLE	IF	CITATIONS
145	Forty Years Fast Forward: Vietnamese Refugees in the United States with Comments on Their Cancer Care. , 2016, , 417-425.		0
146	A Mixed-Methods Feasibility Trial of Protein Kinase C Iota Inhibition with Auranofin in Asymptomatic Ovarian Cancer Patients. <i>Oncology</i> , 2015, 88, 208-213.	0.9	30
147	Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival. <i>BMC Cancer</i> , 2015, 15, 711.	1.1	9
148	Should Vital Signs be Routinely Obtained Prior to Intravenous Chemotherapy? Results from a 2-Center Study. <i>Cancer Control</i> , 2015, 22, 515-519.	0.7	0
149	Nutrition Support in Solid Tumor Cancer Patients. , 2015, , 253-260.		0
150	A Chaplain-led Spiritual Life Review Pilot Study for Patients with Brain Cancers and Other Degenerative Neurologic Diseases. <i>Rambam Maimonides Medical Journal</i> , 2015, 6, e0015.	0.4	7
151	Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers. <i>Supportive Care in Cancer</i> , 2015, 23, 151-157.	1.0	60
152	Radiation-Refractory Brain Metastases in Patients with Non-Small Cell Lung Cancer. <i>Journal of Palliative Medicine</i> , 2015, 18, 707-710.	0.6	0
153	Risk-adjusted outcomes in elderly endometrial cancer patients: Implications of the contrasting impact of age on progression-free and cause-specific survival. <i>Gynecologic Oncology</i> , 2015, 138, 133-140.	0.6	14
154	Hydronephrosis in patients with cervical cancer: an assessment of morbidity and survival. <i>Supportive Care in Cancer</i> , 2015, 23, 1303-1309.	1.0	32
155	Response. <i>Supportive Care in Cancer</i> , 2015, 23, 2213-2213.	1.0	0
156	Incorporating Biomarkers of Frailty and Senescence in Cancer Therapeutic Trials. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015, 70, 722-728.	1.7	23
157	Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. <i>Oncotarget</i> , 2015, 6, 35737-35754.	0.8	23
158	Incidence and Outcomes of Chemotherapy and Radiation in Morbidly Obese Patients with Locally Advanced Lung and Esophageal Cancers: A Single-Institution Experience. <i>Cancer Control</i> , 2014, 21, 63-66.	0.7	2
159	Efficacy of contemporary chemotherapy in stage IIIc endometrial cancer: A histologic dichotomy. <i>Gynecologic Oncology</i> , 2014, 132, 578-584.	0.6	33
160	Non-Small-Cell Lung Cancer in Elderly Patients: A Discussion of Treatment Options. <i>Journal of Clinical Oncology</i> , 2014, 32, 2562-2569.	0.8	44
161	Patients' rationale for declining participation in a cancer-associated weight loss study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014, 5, 121-125.	2.9	8
162	Pemetrexed for Ovarian Cancer: A Systematic Review of the Published Literature and a Consecutive Series of Patients Treated in a Nonclinical Trial Setting. <i>Case Reports in Oncology</i> , 2014, 7, 541-549.	0.3	10

#	ARTICLE	IF	CITATIONS
163	Non-small-cell lung cancer in the elderly with an emphasis on chemotherapy in the adjuvant and metastatic disease settings. <i>Lung Cancer Management</i> , 2014, 3, 411-416.	1.5	0
164	Cancer Cachexia. , 2014, , 620-625.		0
165	Oral Cancer Chemotherapy Adherence and Adherence Assessment Tools: a Report from North Central Cancer Group Trial N0747 and a Systematic Review of the Literature. <i>Journal of Cancer Education</i> , 2013, 28, 770-776.	0.6	20
166	Anti-inflammatory therapy. <i>Current Opinion in Supportive and Palliative Care</i> , 2013, 7, 339-341.	0.5	5
167	A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites. <i>Oncology</i> , 2012, 82, 315-320.	0.9	17
168	Adjuvant chemotherapy and targeted therapy in elderly non-small-cell lung cancer patients. <i>Aging Health</i> , 2012, 8, 309-316.	0.3	2
169	Effect of cigarette smoking on quality of life in small cell lung cancer patients. <i>European Journal of Cancer</i> , 2012, 48, 1593-1601.	1.3	61
170	Is age ≥70years an important predictor of adverse events among patients enrolled in metastatic melanoma trials? Findings from pooled analyses of therapeutic trials. <i>Journal of Geriatric Oncology</i> , 2012, 3, 307-311.	0.5	3
171	Nasal Septal Perforation from Bevacizumab: A Discussion of Outcomes, Management, and Pharmacovigilance. <i>Current Oncology Reports</i> , 2012, 14, 307-310.	1.8	10
172	A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. <i>Medical Oncology</i> , 2012, 29, 1005-1009.	1.2	22
173	Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). <i>Supportive Care in Cancer</i> , 2012, 20, 1729-1735.	1.0	17
174	Who is Counseled to Lose Weight? Survey Results and Anthropometric Data from 3,149 Lower Socioeconomic Women. <i>Journal of Community Health</i> , 2012, 37, 202-207.	1.9	11
175	Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 314-314.	0.8	8
176	Is Spanish Language a Barrier to Domestic Violence Assessment?. <i>Journal of Women's Health</i> , 2011, 20, 1111-1116.	1.5	4
177	Exploring Therapeutic Decisions in Elderly Patients with Non-Small Cell Lung Cancer: Results and Conclusions from North Central Cancer Treatment Group Study N0222. <i>Cancer Investigation</i> , 2011, 29, 266-271.	0.6	4
178	Integrative and complementary medicine among cancer patients: At what price?. <i>European Journal of Integrative Medicine</i> , 2011, 3, e139-e141.	0.8	2
179	Integrative nutritional approaches to loss of weight and appetite in patients with advanced cancer. <i>European Journal of Integrative Medicine</i> , 2011, 3, e233-e236.	0.8	1
180	Definition and classification of cancer cachexia: an international consensus. <i>Lancet Oncology</i> , The, 2011, 12, 489-495.	5.1	4,015

#	ARTICLE	IF	CITATIONS
181	Fatigue, Dyspnea, and Cough Comprise a Persistent Symptom Cluster Up to Five Years After Diagnosis with Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2011, 42, 202-212.	0.6	59
182	Parenteral Nutrition in Patients With Advanced Cancer: Merging Perspectives From the Patient and Healthcare Provider. <i>Seminars in Oncology</i> , 2011, 38, 439-442.	0.8	6
183	Former Military Officers from the Republic of Vietnam Now Living in the United States (US): Exploring their Perceptions of the US Healthcare System. <i>Journal of Community Health</i> , 2011, 36, 992-998.	1.9	4
184	Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary) <i>TJ ETQq0 0 0 rgBT 10 rlock 10 Tf 50 6</i>	1.0	11
185	An overview of the European Society of Medical Oncology (ESMO) Symposium on Cancer and Nutrition 2009: from cancer prevention to nutrition support to alleviating suffering in patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2011, 19, 1895-1898.	1.0	2
186	Consumer Beware: A Systematic Assessment of Potential Bias in the Lay Electronic Media to Examine the Portrayal of PARP Inhibitors for Cancer Treatment. <i>Journal of Cancer Education</i> , 2011, 26, 474-477.	0.6	1
187	Practical Strategies to Circumvent and/or Surmount Six Barriers in Health Disparities Research: Observations from a Pilot Project Among Vietnamese Americans. <i>Journal of Cancer Education</i> , 2011, 26, 243-247.	0.6	4
188	How Important is Palliative Care?. <i>Current Oncology Reports</i> , 2011, 13, 252-254.	1.8	4
189	A qualitative study of the ramifications of rash from epidermal growth factor receptor (EGFR) inhibitors. <i>Psycho-Oncology</i> , 2011, 20, 1246-1249.	1.0	11
190	Adjuvant Chemotherapy in Colon Cancer: Ageism or Appropriate Care?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3209-3210.	0.8	11
191	Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash: A Consecutive Patient Series that Illustrates the Need for Rigorous Palliative Trials. <i>Journal of Palliative Medicine</i> , 2011, 14, 153-156.	0.6	10
192	Bevacizumab-induced nasal septal perforation: Incidence of symptomatic, confirmed event(s) in colorectal cancer patients. <i>Acta Oncológica</i> , 2011, 50, 578-581.	0.8	17
193	The Purported Effects of Alcohol on Appetite and Weight in Lung Cancer Patients. <i>Nutrition and Cancer</i> , 2011, 63, 1251-1255.	0.9	2
194	Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. <i>International Journal of Oncology</i> , 2010, 36, 601-6.	1.4	43
195	Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal Junction Tumors. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1994-1998.	0.5	21
196	Cancer chemotherapy: with or without food?. <i>Supportive Care in Cancer</i> , 2010, 18, 13-16.	1.0	2
197	The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer. <i>Supportive Care in Cancer</i> , 2010, 18, 1299-1304.	1.0	16
198	Cancer Patients and Their Companion Animals: Results from a 309-Patient Survey on Pet-Related Concerns and Anxieties During Chemotherapy. <i>Journal of Cancer Education</i> , 2010, 25, 396-400.	0.6	21

#	ARTICLE	IF	CITATIONS
199	STEPP for the EGFR Inhibitorâ€“Induced Rashâ€“Definitely a Step in the Right Direction. <i>Current Oncology Reports</i> , 2010, 12, 223-225.	1.8	2
200	Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient Safety. <i>Current Oncology Reports</i> , 2010, 12, 247-252.	1.8	73
201	Marital Status and Quality of Life in Patients with Esophageal Cancer or Barrett's Esophagus: The Mayo Clinic Esophageal Adenocarcinoma and Barrett's Esophagus Registry Study. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2860-2868.	1.1	21
202	Capecitabine and Temozolomide: Design, Implementation, and Preliminary Outcomes From a Pilot Project to Ensure Safe Prescribing of Oral Chemotherapy. <i>Journal of Oncology Practice</i> , 2010, 6, 210-212.	2.5	4
203	Parenteral nutrition in patients with cancer: recent guidelines and a need for further study. <i>Current Opinion in Supportive and Palliative Care</i> , 2010, 4, 272-275.	0.5	5
204	Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitorâ€“Induced Rash? Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N05C4). <i>Oncologist</i> , 2010, 15, 1016-1022.	1.9	52
205	E-Mail and Photographs: A Case Report of a Patient-Initiated Diagnostic Tool in the Era of Electronic Communication. <i>Journal of Palliative Medicine</i> , 2010, 13, 335-337.	0.6	6
206	A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). <i>Lung Cancer</i> , 2010, 68, 234-239.	0.9	167
207	Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147. <i>Oncology</i> , 2009, 77, 120-123.	0.9	67
208	Search for Evidence-Based Approaches for the Prevention and Palliation of Handâ€“Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs). <i>Oncologist</i> , 2009, 14, 291-302.	1.9	103
209	Cumulative Morbidity and Late Mortality in Long-Term Survivors of Exocrine Pancreas Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2009, 40, 46-50.	0.6	11
210	Bisphosphonates: Preventing skeletal morbidity and maybe doing more. <i>Current Oncology Reports</i> , 2009, 11, 251-252.	1.8	0
211	If You Hold It Off-Hours, Will They Come? Results from a Feasibility Project Intended to Stimulate Interest in the Physician-Investigator Career Path Among Medical Oncology Trainees. <i>Journal of Cancer Education</i> , 2009, 24, 200-203.	0.6	2
212	Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival. <i>Annals of Thoracic Surgery</i> , 2009, 87, 392-399.	0.7	240
213	Osseous metastases: drugs that enhance bone integrity and prevent adverse skeletal events. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 723-726.	0.9	2
214	Overview of the management of the anorexia/weight loss syndrome. , 2009, , 538-545.		0
215	Palliating hiccups in cancer patients: moving beyond recommendations from Leonard the lion. <i>The Journal of Supportive Oncology</i> , 2009, 7, 129-30.	2.3	4
216	In search of rigorous data on how to palliate the EGFR inhibitor-induced rash. <i>Oncology</i> , 2009, 23, 196, 198.	0.4	0

#	ARTICLE	IF	CITATIONS
217	Rash from EGFR inhibitors: Opportunities and challenges for palliation. <i>Current Oncology Reports</i> , 2008, 10, 304-308.	1.8	17
218	An Update on Advance Directives in the Medical Record: Findings from 1186 Consecutive Patients with Unresectable Exocrine Pancreas Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2008, 39, 100-103.	0.6	16
219	Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report. <i>Psycho-Oncology</i> , 2008, 17, 721-725.	1.0	20
220	Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes. <i>Cancer</i> , 2008, 113, 847-853.	2.0	167
221	A Survey of Patient Advocates within the National Cancer Institute's Prostate Cancer SPORE Program: Who are They? What Motivates Them? What Might They Tell Us?. <i>Journal of Cancer Education</i> , 2008, 23, 222-225.	0.6	4
222	Cachexia: A new definition. <i>Clinical Nutrition</i> , 2008, 27, 793-799.	2.3	1,906
223	Are Cancer Survivors/Patients Knowledgeable About Osteoporosis? Results from a Survey of 285 Chemotherapy-treated Cancer Patients and Their Companions. <i>Journal of Nutrition Education and Behavior</i> , 2008, 40, 144-148.	0.3	20
224	Motivational readiness for physical activity and quality of life in long-term lung cancer survivors. <i>Lung Cancer</i> , 2008, 61, 117-122.	0.9	67
225	Do Patients Die from Rashes from Epidermal Growth Factor Receptor Inhibitors? A Systematic Review to Help Counsel Patients About Holding Therapy. <i>Oncologist</i> , 2008, 13, 1201-1204.	1.9	34
226	Side effects and pharmaceutical company bias: adverse event reporting in cancer supportive and palliative care trials. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1787-1790.	1.9	4
227	Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B). <i>Journal of Thoracic Oncology</i> , 2008, 3, 516-520.	0.5	36
228	Weight loss in patients with advanced cancer: effects, causes, and potential management. <i>Current Opinion in Supportive and Palliative Care</i> , 2008, 2, 45-48.	0.5	26
229	Does dietary counseling improve quality of life in cancer patients? A systematic review and meta-analysis. <i>The Journal of Supportive Oncology</i> , 2008, 6, 234-7.	2.3	24
230	Does Marital Status Impact Survival and Quality of Life in Patients with Non-Small Cell Lung Cancer? Observations from the Mayo Clinic Lung Cancer Cohort. <i>Oncologist</i> , 2007, 12, 1456-1463.	1.9	67
231	Wine for Appetite Loss: "How Do You Know?" <i>Journal of Clinical Oncology</i> , 2007, 25, 1285-1287.	0.8	6
232	Wanted "and Needed" More Studies in Geriatric Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2007, 2, 103-104.	0.5	2
233	Who should receive parenteral nutrition or pharmacologic therapy for loss of appetite and weight in the setting of incurable cancer?. <i>Current Opinion in Supportive and Palliative Care</i> , 2007, 1, 279-280.	0.5	0
234	Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation for Locally Advanced Esophageal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 507-513.	0.6	25

#	ARTICLE	IF	CITATIONS
235	A Critical Look at the Role of Chemotherapy in Older Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 83-90.	0.5	0
236	Current Management Strategies for Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 751-770.	1.4	127
237	A Tomato-Based, Lycopene-Containing Intervention for Androgen-Independent Prostate Cancer: Results of a Phase II Study from The North Central Cancer Treatment Group. <i>Urology</i> , 2007, 69, 289-294.	0.5	71
238	Pharmacological options for advanced cancer patients with loss of appetite and weight. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1085-1090.	0.9	27
239	Current Management Strategies for Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 751-770.	1.4	156
240	Sunshine and Rash: Testing the Role of Sunscreen to Prevent Epidermal Growth Factor Receptor Inhibitor-Induced Rash. <i>Supportive Cancer Therapy</i> , 2007, 4, 198-202.	0.3	5
241	The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. <i>Cancer</i> , 2007, 110, 363-368.	2.0	54
242	A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome. <i>Cancer</i> , 2007, 110, 1396-1403.	2.0	120
243	Does Zinc Sulfate Prevent Therapy-Induced Taste Alterations in Head and Neck Cancer Patients? Results of Phase III Double-Blind, Placebo-Controlled Trial from the North Central Cancer Treatment Group (N01C4). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1318-1322.	0.4	100
244	Shopping for nutrition-based complementary and alternative medicine on the internet: How much money might cancer patients be spending online?. <i>Journal of Cancer Education</i> , 2007, 22, 174-176.	0.6	12
245	A Critical Look at the Role of Chemotherapy in Older Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 83-90.	0.5	3
246	Nutrition and Cancer. <i>Nutrition and Disease Prevention</i> , 2007, , 421-432.	0.1	0
247	Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. <i>The Journal of Supportive Oncology</i> , 2007, 5, 41-6.	2.3	10
248	A critical look at the role of chemotherapy in older patients with non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 83-90.	0.5	1
249	An Update on Therapeutics: The Cancer Anorexia/Weight Loss Syndrome in Advanced Cancer Patients. , 2006, , 643-648.		0
250	A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341.) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf 5</i> <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 207-215.	1.1	41
251	New agents, new rashes: An update on skin complications from cancer chemotherapy. <i>Current Oncology Reports</i> , 2006, 8, 269-274.	1.8	3
252	Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. <i>Clinical Nutrition</i> , 2006, 25, 711-715.	2.3	25

#	ARTICLE	IF	CITATIONS
253	Helping people cope with bereavement: an opportunity for health care providers to link Web-based resources across Minnesota. <i>Minnesota Medicine</i> , 2006, 89, 42-4.	0.1	0
254	Pharmacologic therapy for the cancer anorexia/weight loss syndrome: A data-driven, practical approach. <i>The Journal of Supportive Oncology</i> , 2006, 4, 499-502.	2.3	11
255	Fish oil, lean tissue, and cancer: is there a role for eicosapentaenoic acid in treating the cancer anorexia/weight loss syndrome?. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 55, 37-43.	2.0	11
256	Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition?. <i>Cancer</i> , 2005, 103, 863-868.	2.0	106
257	Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. <i>Supportive Care in Cancer</i> , 2005, 13, 66-69.	1.0	31
258	Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. <i>Supportive Care in Cancer</i> , 2005, 13, 381-386.	1.0	29
259	The cancer anorexia/weight loss syndrome: Therapeutic challenges. <i>Current Oncology Reports</i> , 2005, 7, 271-276.	1.8	28
260	Should Elderly Non-Small-Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 9113-9119.	0.8	116
261	© Fatty Acid Supplements for Cancer-Associated Weight Loss. <i>Nutrition in Clinical Practice</i> , 2005, 20, 394-399.	1.1	5
262	Targeting and Palliating Malignant Ascites: An Overview of an Upcoming Clinical Trial from the North Central Cancer Treatment Group. <i>Supportive Cancer Therapy</i> , 2005, 3, 59-62.	0.3	4
263	Exploring Vitamin and Mineral Supplementation and Purported Clinical Effects in Patients With Small Cell Lung Cancer: Results From the Mayo Clinic Lung Cancer Cohort. <i>Nutrition and Cancer</i> , 2005, 51, 7-12.	0.9	21
264	Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients?. <i>Lung Cancer</i> , 2005, 49, 77-84.	0.9	35
265	Tumor Necrosis Factor Inhibitors in Cancer-Associated Weight Loss Syndrome. , 2005, , 473-487.		0
266	An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort. <i>Journal of Clinical Oncology</i> , 2004, 22, 2469-2476.	0.8	256
267	Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: preliminary analyses and treatment recommendations from the North Central Cancer Treatment Group. <i>International Seminars in Surgical Oncology</i> , 2004, 1, 9.	1.1	8
268	Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. <i>Supportive Care in Cancer</i> , 2004, 12, 640-4.	1.0	14
269	A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. <i>Supportive Care in Cancer</i> , 2004, 12, 859-863.	1.0	31
270	Tumor Necrosis Factor- α as a Treatment Target for the Cancer Anorexia/Weight Loss Syndrome. <i>Supportive Cancer Therapy</i> , 2004, 1, 237-242.	0.3	3

#	ARTICLE	IF	CITATIONS
271	Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. <i>Lung Cancer</i> , 2004, 43, 345-353.	0.9	41
272	Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer. <i>The Journal of Supportive Oncology</i> , 2004, 2, 323-34; discussion 334-7.	2.3	24
273	A Phase II Trial of Docetaxel and CPT-11 in Patients with Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia. <i>International Journal of Gastrointestinal Cancer</i> , 2003, 32, 115-124.	0.4	34
274	A Phase II Study of Topical Ceramides for Cutaneous Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 80, 99-104.	1.1	25
275	Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients. <i>Supportive Care in Cancer</i> , 2003, 11, 460-464.	1.0	23
276	Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine?. <i>Seminars in Oncology</i> , 2003, 30, 72-75.	0.8	2
277	A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. <i>Cancer</i> , 2003, 97, 1442-1446.	2.0	274
278	Fat, fish oil and the cancer anorexia/weight loss syndrome. <i>Evidence - Based Integrative Medicine</i> , 2003, 1, 51-55.	0.2	0
279	The Outcome of Combined-Modality Therapy for Stage III Non-Small-Cell Lung Cancer in the Elderly. <i>Journal of Clinical Oncology</i> , 2003, 21, 3201-3206.	0.8	223
280	Weekly Carboplatin and Paclitaxel in Elderly Non-Small-Cell Lung Cancer Patients (≥ 65 Years of Age). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 441-447.	0.6	29
281	Loss of appetite and weight. , 2003, , 369-373.		0
282	On Appetite and Its Loss. <i>Journal of Clinical Oncology</i> , 2003, 21, 79s-81.	0.8	35
283	Why should we care about the cancer anorexia/weight loss syndrome?. <i>Oncology</i> , 2003, 17, 5-6.	0.4	0
284	Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. <i>The Journal of Supportive Oncology</i> , 2003, 1, 274-8.	2.3	34
285	Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 567-573.	0.8	279
286	Anorexia. <i>American Journal of Cancer</i> , 2002, 1, 269-275.	0.4	0
287	Comparative Efficacy of Dronabinol and Megestrol Acetate. <i>Journal of Clinical Oncology</i> , 2002, 20, 2912-2913.	0.8	12
288	Adenosine Triphosphate: Does It Help Cancer Patients "Get Bigger and Stronger"? <i>Journal of Clinical Oncology</i> , 2002, 20, 362-363.	0.8	6

#	ARTICLE	IF	CITATIONS
289	Esophageal cancer and the esophagus: Challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment. <i>Seminars in Radiation Oncology</i> , 2002, 12, 62-67.	1.0	18
290	Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. <i>Supportive Care in Cancer</i> , 2002, 10, 71-75.	1.0	28
291	Does megestrol acetate down-regulate interleukin-6 in cancer-associated anorexia?. <i>Supportive Care in Cancer</i> , 2002, 10, 568-568.	1.0	0
292	Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure?. <i>Annals of Thoracic Surgery</i> , 2001, 72, 348-351.	0.7	48
293	An update: cancer-associated anorexia as a treatment target. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2001, 4, 179-182.	1.3	13
294	Folate status among patients with non-small cell lung cancer: A case-control study. <i>Journal of Surgical Oncology</i> , 2001, 77, 247-252.	0.8	19
295	Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia. <i>Cancer</i> , 2001, 92, 629-633.	2.0	29
296	On Appetite and Its Loss. <i>Journal of Clinical Oncology</i> , 2000, 18, 2930-2932.	0.8	50
297	The prognostic effect of increased resting energy expenditure prior to treatment for lung cancer. <i>Lung Cancer</i> , 1999, 23, 153-158.	0.9	24
298	Nutritional support of critically ill cancer patients. , 0, , 147-154.		0
299	Cancer anorexia/weight loss syndrome: clinical science. , 0, , 142-150.		0
300	Esophageal Adenocarcinoma. , 0, , 31-113.		0